RICHARD J WHITLEY, M.D.
Medical Practice in Birmingham, AL

License number

Alabama 6475

Organization information

See more information about RICHARD J WHITLEY at bizstanding.com

University Of Alabama-Peds - Richard J Whitley MD

1600 7 Ave S #303, Birmingham, AL 35233

Categories:

Pediatrics Physicians & Surgeons

Phone:

(205) 996-7782 (Phone)

Professional information

See more information about RICHARD J WHITLEY at trustoria.com

Professor At Uab

Position:

Professor at UAB, Professor at University of Alabama at Birmingham

Location:

Birmingham, Alabama Area

Industry:

Research

Work:

UAB - Professor University of Alabama at Birmingham since 1976 - Professor

Education:

The George Washington University School of Medicine and Health Sciences 1967 - 1971
MD, Medicine Duke University 1963 - 1967
BA, Chemistry

Richard James Whitley, Birmingham AL

Specialties:

Pediatrics, Pediatric Infectious Diseases, Infectious Disease

Work:

Children's Hospital of Alabama
1600 7Th Ave S, Birmingham, AL 35233 Midtown Pediatrics
1400 4Th Ave S, Birmingham, AL 35233

Education:

George Washington University (1971)

Dr. Richard J Whitley, Birmingham AL - MD (Doctor of Medicine)

Specialties:

Pediatric Infectious Disease Medicine

Address:

1600 7Th Ave S, Birmingham 35233

Certifications:

Pediatric Infectious Disease Medicine, 1994, Pediatrics, 1976

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
George Washington University School Of Medicine
Graduated: 1971
Chldns Hospital Ala
Graduated: 1972
Graduated: 1973
Graduated: 1976

Herpes Simplex Virus Expressing Foreign Genes And Method For Treating Cancers Therewith

US Patent:

6764675, Jul 20, 2004

Filed:

Feb 14, 2002

Appl. No.:

10/009972

Inventors:

Richard J. Whitley - Birmingham AL
James MacDowell Markert - Birmingham AL
George Yancey Gillespie - Birmingham AL
Jacqueline Ness Parker - Brimingham AL

Assignee:

The UAB Research Foundation - Birmingham AL

International Classification:

A01N 6300

US Classification:

424 932, 514 44, 4353201, 435455, 435456

Abstract:

An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition including an HSV vector having a nucleic acid sequence encoding an anti-cancer agent selected from interleukin-12, GM-CSF, and CD inserted therein.

Methods And Compositions For Cytokine Expression And Treatment Of Tumors

US Patent:

2008009, Apr 24, 2008

Filed:

Nov 1, 2005

Appl. No.:

11/718439

Inventors:

Jacqueline Parker - Birmingham AL, US
Richard Whitley - Birmingham AL, US
James Markert - Birmingham AL, US

International Classification:

A61K 39/245, C12N 7/01, A61P 35/00

US Classification:

424093200, 435235100

Abstract:

A conditionally replicating, aneurovirulent recombinant herpes simplex virus is provided that includes a nucleic acid encoding an expressible chemokine. An expression control element is operably linked to the nucleic acid. A therapeutic composition includes a first conditionally replicating, aneurovirulent recombinant herpes simplex virus having a first nucleic acid encoding a first expressible cytokine operatively linked to an expression control element. A second such herpes simplex virus encoding a second expressible cytokine is also provided with a pharmaceutically acceptable carrier. Preferably, the second cytokine is a chemokine. In a particular embodiment, the first expressible cytokine increases availability of an immunoresponsive cell for activation. The activatable cell is CD4+, CD8+, NK, a dendritic cell, or a combination thereof. A second conditionally replicating, aneurovirulent, recombinant herpes simplex virus expresses a second cytokine in the same host cell as the first virus or alternatively, upon expression in a second host cell, resulting in the activation of the immunoresponsive cell. A method of tumor cell growth inhibition is provided that includes introduction of a therapeutically effective amount of an aforementioned therapeutic composition into a tumor of an individual such that two different cytokines are produced within the tumor to enhance the immune response in the individual that inhibits tumor cell growth. The first and second recombinant herpes simplex viruses are administered simultaneously, sequentially. Sequential administration is separated by a time period ranging from a few second to several days.

Herpes Simplex Virus Expressing Foreign Genes And Method For Treating Cancers Therewith

US Patent:

2004025, Dec 23, 2004

Filed:

Jul 8, 2004

Appl. No.:

10/886907

Inventors:

Richard Whitley - Birmingham AL, US
James Markert - Birmingham AL, US
George Gillespie - Birmingham AL, US
Jacqueline Parker - Birmingham AL, US

International Classification:

A61K048/00

US Classification:

424/093200

Abstract:

An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition including a HSV vector having a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD inserted therein.

Recombinant Herpes Simplex Virus Useful For Treating Neoplastic Disease

US Patent:

7744899, Jun 29, 2010

Filed:

Oct 11, 2006

Appl. No.:

11/546233

Inventors:

Richard J. Whitley - Birmingham AL, US
Bernard Roizman - Chicago IL, US

Assignee:

The University of Chicago - Chicago IL
UAB Research Foundation - Birmingham AL

International Classification:

C12N 15/869, A61K 48/00

US Classification:

4241991, 514 44 R, 4353201

Abstract:

Recombinant herpes simplex viruses comprising DNA encoding cytokines and methods for treating neoplastic diseases using the inventive recombinant viruses are disclosed.